MYC Antibody
Cat# OAEE01020
Size : 0.1mg(C100)
Brand : Aviva Systems Biology
Contact local distributor :
Phone : +1 850 650 7790
| Datasheets/Manuals | Printable datasheet for MYC Antibody |
|---|
| Predicted Species Reactivity | Human |
|---|---|
| Product Format | Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide |
| Clonality | Monoclonal |
| Clone | 9E10 |
| Isotype | IgG1 |
| Host | Mouse |
| Conjugation | FITC |
| Application | FC|FC-I |
| Reconstitution and Storage | 2°C to 8°C |
| Immunogen | Synthetic peptide sequence (AEEQKLISEEDLL) corresponding to the C-terminal region of human c-Myc. |
| Purification | Purified by size-exclusion chromatography |
| Concentration | 1 mg/ml |
| Specificity | The antibody 9E10 may be used to detect the c-Myc tag. The c-myc gene (8q24 on human chromosome) is the cellular homologue of the v-myc gene originally isolated from an avian myelocytomatosis virus. The c-Myc protein is a transcription factor (nuclear localization). c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin-dependent kinase, ERK2 and C-Jun N-terminal Kinase (JNK) in cell proliferation and cell cycle regulation. In normal cells the expression of c-Myc is tightly regulated but in human cancers c-Myc is frequently deregulated. c-Myc is also essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells. |
| Formulation | FITC |
| Storage Buffer | Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4 |
| Reference | Cermák L, Símová S, Pintzas A, Horejsí V, Andera L: Molecular mechanisms involved in CD43-mediated apoptosis of TF-1 cells. Roles of transcription Daxx expression, and adhesion molecules. J Biol Chem. 2002 Mar 8;277(10):7955-61. Hilpert K, Hansen G, Wessner H, Kuttner G, Welfle K, Seifert M, Hohne W: Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. Protein Eng. 2001 Oct;14(10):803-6. Veracini L, Simon V, Richard V, Schraven B, Horejsi V, Roche S, Benistant C: The Csk-binding protein PAG regulates PDGF-induced Src mitogenic signaling via GM1. J Cell Biol. 2008 Aug 11;182(3):603-14. Siegel J, Brandner G, Hess RD: Cross-reactivity of the monoclonal antibody 9E10 with murine c-MYC. Int J Oncol. 1998 Dec;13(6):1259-62. Wang X, Campoli M, Ko E, Luo W, Ferrone S: Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.J Immunol Methods. 2004 Nov;294(1-2):23-35. Fujiwara K, Poikonen K, Aleman L, Valtavaara M, Saksela K, Mayer BJ: A single-chain antibody/epitope system for functional analysis of protein-protein interactions. Biochemistry. 2002 Oct 22;41(42):12729-38. Baggio R, Burgstaller P, Hale SP, Putney AR, Lane M, Lipovsek D, Wright MC, Roberts RW, Liu R, Szostak JW, Wagner RW: Identification of epitope-like consensus motifs using mRNA display. J Mol Recognit. 2002 May-Jun;15(3):126-34. Spandidos DA et al. 1987. Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. Anticancer Res 7:1299-304., Persson H, Hennighausen L, Taub R, DeGrado W, Leder P: Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science. 1984 Aug 17;225(4663):687-93., Evan GI et al. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 5:3610-6., Prendergast GC. 1999. Mechanisms of apoptosis by c-Myc. Oncogene 18(19):2967-2987., Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K. 1999. Function of the c-Myc oncogenic transcription factor. Exp Cell Res 253(1): 63-77., Boxer LM, Dang CV. 2001. Translocations involving c-myc and c-myc function. Oncogene 20(40):5595-5610., Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. 2002. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21(21): 3414-3421. |
|---|---|
| Gene Symbol | MYC |
| Gene Full Name | MYC proto-oncogene, bHLH transcription factor |
| Alias Symbols | avian myelocytomatosis viral oncogene homolog, bHLHe39, c-Myc, class E basic helix-loop-helix protein 39, MRTL, myc proto-oncogene protein, myc-related translation/localization regulatory factor, MYCC, proto-oncogene c-Myc, transcription factor p64, v-myc avian myelocytomatosis viral oncogene homolog, v-myc myelocytomatosis viral oncogene homolog. |
| NCBI Gene Id | 4609 |
| Protein Name | Myc proto-oncogene protein |
| Description of Target | Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis (PubMed:24940000). |
| Uniprot ID | P01106 |
| Protein Accession # | NP_002458.2 |
| Nucleotide Accession # | NM_002467.4 |
